- Home
- FBRX vs PULM Comparison
FBRX vs PULM Comparison
Compare FBRX & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBRX
- PULM
- Stock Information
- Founded
- FBRX N/A
- PULM 2003
- Country
- FBRX United States
- PULM United States
- Employees
- FBRX N/A
- PULM N/A
- Industry
- FBRX Biotechnology: Pharmaceutical Preparations
- PULM Biotechnology: Pharmaceutical Preparations
- Sector
- FBRX Health Care
- PULM Health Care
- Exchange
- FBRX Nasdaq
- PULM Nasdaq
- Market Cap
- FBRX 69.7M
- PULM 33.2M
- IPO Year
- FBRX N/A
- PULM N/A
- Fundamental
- Price
- FBRX $12.49
- PULM $6.46
- Analyst Decision
- FBRX Strong Buy
- PULM
- Analyst Count
- FBRX 2
- PULM 0
- Target Price
- FBRX $61.00
- PULM N/A
- AVG Volume (30 Days)
- FBRX 177.7K
- PULM 60.4K
- Earning Date
- FBRX 08-13-2025
- PULM 08-12-2025
- Dividend Yield
- FBRX N/A
- PULM N/A
- EPS Growth
- FBRX N/A
- PULM N/A
- EPS
- FBRX N/A
- PULM N/A
- Revenue
- FBRX N/A
- PULM $1,921,000.00
- Revenue This Year
- FBRX N/A
- PULM N/A
- Revenue Next Year
- FBRX N/A
- PULM $134.88
- P/E Ratio
- FBRX N/A
- PULM N/A
- Revenue Growth
- FBRX N/A
- PULM N/A
- 52 Week Low
- FBRX $4.11
- PULM $1.78
- 52 Week High
- FBRX $28.68
- PULM $10.40
- Technical
- Relative Strength Index (RSI)
- FBRX 52.54
- PULM 39.79
- Support Level
- FBRX $10.15
- PULM $6.26
- Resistance Level
- FBRX $14.49
- PULM $6.96
- Average True Range (ATR)
- FBRX 1.93
- PULM 0.87
- MACD
- FBRX -0.20
- PULM -0.12
- Stochastic Oscillator
- FBRX 23.31
- PULM 40.16
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).